Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology company focused on PLK1 inhibition for cancer therapies, has announced it will release its fourth quarter 2024 financial results on Thursday, February 27, 2025. The company will host a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT following market close.
Interested parties can access the webcast through the 'Investors' section of Cardiff Oncology's website. A replay of the call will be made available in the investor relations section afterward.
Cardiff Oncology (Nasdaq: CRDF), un'azienda biotecnologica in fase clinica focalizzata sull'inibizione di PLK1 per le terapie oncologiche, ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre 2024 giovedì 27 febbraio 2025. L'azienda ospiterà una conferenza telefonica e un webcast alle 16:30 ET/13:30 PT dopo la chiusura del mercato.
Le parti interessate possono accedere al webcast tramite la sezione 'Investitori' del sito web di Cardiff Oncology. Una registrazione della chiamata sarà disponibile nella sezione relazioni con gli investitori in seguito.
Cardiff Oncology (Nasdaq: CRDF), una empresa biotecnológica en etapa clínica centrada en la inhibición de PLK1 para terapias contra el cáncer, ha anunciado que publicará sus resultados financieros del cuarto trimestre de 2024 el jueves 27 de febrero de 2025. La empresa llevará a cabo una conferencia telefónica y un webcast a las 4:30 p.m. ET/1:30 p.m. PT después del cierre del mercado.
Las partes interesadas pueden acceder al webcast a través de la sección 'Inversores' del sitio web de Cardiff Oncology. Una grabación de la llamada estará disponible en la sección de relaciones con inversores posteriormente.
카디프 온콜로지(Cardiff Oncology, Nasdaq: CRDF)는 암 치료를 위한 PLK1 억제에 중점을 둔 임상 단계의 생명공학 회사로, 2024년 4분기 재무 결과를 2025년 2월 27일 목요일에 발표할 것이라고 발표했습니다. 회사는 시장 종료 후 오후 4시 30분 ET/오후 1시 30분 PT에 컨퍼런스 콜 및 웹캐스트를 개최할 예정입니다.
관심 있는 당사자는 카디프 온콜로지 웹사이트의 '투자자' 섹션을 통해 웹캐스트에 접근할 수 있습니다. 이후 투자자 관계 섹션에서 통화 녹화본을 제공할 예정입니다.
Cardiff Oncology (Nasdaq: CRDF), une entreprise biopharmaceutique en phase clinique axée sur l'inhibition de PLK1 pour les thérapies contre le cancer, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre 2024 le jeudi 27 février 2025. L'entreprise organisera une conférence téléphonique et un webinaire à 16h30 ET/13h30 PT après la fermeture du marché.
Les parties intéressées peuvent accéder au webinaire via la section 'Investisseurs' du site Web de Cardiff Oncology. Un enregistrement de l'appel sera disponible par la suite dans la section des relations avec les investisseurs.
Cardiff Oncology (Nasdaq: CRDF), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Hemmung von PLK1 für Krebstherapien konzentriert, hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal 2024 am Donnerstag, den 27. Februar 2025, veröffentlichen wird. Das Unternehmen wird nach Marktschluss um 16:30 Uhr ET/13:30 Uhr PT eine Telefonkonferenz und einen Webcast veranstalten.
Interessierte Parteien können auf den Webcast über den Bereich 'Investoren' der Cardiff Oncology-Website zugreifen. Eine Wiederholung des Anrufs wird anschließend im Bereich für Investor Relations verfügbar sein.
- None.
- None.
- Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET/1:30 p.m. PT -
SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will hold a conference call on Thursday, February 27 after the close of trading to review financial results for the fourth quarter ended December 31, 2024.
Conference Call and Webcast
Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on February 27, 2025. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://investors.cardiffoncology.com/news-events/events. A replay will be available in the investor relations section on the company's website following the completion of the call.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing and planned investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com
Investor Contact:
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com
Media Contact:
Grace Spencer
Taft Communications
609-583-1151
grace@taftcommunications.com
FAQ
When will Cardiff Oncology (CRDF) report Q4 2024 earnings?
What time is Cardiff Oncology's (CRDF) Q4 2024 earnings call?
How can investors access Cardiff Oncology's (CRDF) Q4 2024 earnings call?
Will there be a replay available for Cardiff Oncology's (CRDF) Q4 2024 earnings call?
